Ultragenyx Pharmaceutical Inc. reaffirmed earnings guidance for the full year 2024. For the year, the company reaffirms total revenue in the range of $500 million to $530 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.24 USD | +0.89% | +4.41% | -7.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.49% | 3.64B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024